CAR T Cell Immunotherapy for Lymphoma & Leukemia - T. Shea - 20160608

Dr. Thomas Shea, MD discusses the biology behind the use of Chimeric Antigen Receptor (CAR) for T cell Immunotherapy, including current indications and general results. Learning Outcomes: • Explain biology behind the use of Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy. • Describe the current indications for CAR-T cell therapy. • Discuss the general results with CAR-T cell therapy. This lecture was presented as a part of the Medical and Surgical Oncology Lecture Series and the RN and Allied Health Lectures.

Thomas Shea MD, Director of the UNC Cancer Network

6/8/2016 3:30:00 PM